GSK3B and Alzheimer disease: In any case, an appreciable battery of kinase inhibitors has been probed in AD drugs to slow down the phosphorylation process, principally targeting the GSK-3β enzyme, but also inhibiting CdK-5, PKA, CaMKII or ERK1/2, among others [122].